Skip to main content
. 2011 May 3;2011:915240. doi: 10.1093/ecam/nep237

Table 3.

Electro-cardiograms (ECG) variables demonstrating cardiovascular safety of CA extracts.

Control (0.5% NaCMC) C. auriculata (mg kg−1)
HA SFE
500 1000 250 500 1000
Males
 QT interval(s) 7.0 ± 1.2 7.1 ± 1.5 6.5 ± 0.6 7.0 ± 0.5 7.5 ± 0.3 6.8 ± 2.5
 R wave amplitude (μV) 225 ± 66 250 ± 65 200 ± 69 250 ± 55 300 ± 54 350 ± 48
 R-R interval(s) 0.3 ± 0.01 0.25 ± 0.01 0.22 ± 0.05 0.29 ± 0.03 0.22 ± 0.08 0.28 ± 0.09
Females
 QT interval(s) 7.5 ± 1.9 6.0 ± 1.0 7.2 ± 0.4 7.2 ± 0.8 7.9 ± 0.9 6.0 ± 1.2
 R wave amplitude (μV) 255 ± 92 220 ± 55 255 ± 169 253 ± 68 210 ± 120 220 ± 96
 R-R interval(s) 0.22 ± 0.02 0.19 ± 0.02 0.20 ± 0.03 0.23 ± 0.03 0.29 ± 0.05 0.30 ± 0.09

Data are expressed as mean ± SD, n = 6. No significant difference in heart rate (R-R interval), QT interval (diastolic dysfunction) and ventricular hypertrophy (R wave amplitude) observed at increasing doses of both CA-HA and CA-SFE demonstrates safety of CA extracts.